What is the difference between erysipelas and cellulitis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 11, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Erysipelas and cellulitis are distinct bacterial skin infections that differ in their depth and presentation, with erysipelas affecting the upper dermis and superficial lymphatics, and cellulitis involving the deeper dermis and subcutaneous fat. The key differences between erysipelas and cellulitis lie in their clinical presentation and the depth of skin involvement. Erysipelas is characterized by a well-demarcated, raised, bright red, painful rash with a clear border between infected and normal skin, commonly occurring on the face and legs, and often accompanied by fever and systemic symptoms 1. In contrast, cellulitis involves the deeper dermis and subcutaneous fat, appearing as a less defined, spreading area of redness, warmth, pain, and swelling without the raised edges characteristic of erysipelas, with a typically blurry border between infected and normal skin 1. Some key points to consider when differentiating between erysipelas and cellulitis include:

  • The depth of skin involvement, with erysipelas affecting the upper dermis and superficial lymphatics, and cellulitis involving the deeper dermis and subcutaneous fat 1
  • The presence of a clear border between infected and normal skin in erysipelas, versus a blurry border in cellulitis 1
  • The common causes of each condition, with erysipelas typically caused by streptococcal species, and cellulitis caused by streptococci and Staphylococcus aureus 1
  • The treatment approaches for each condition, which typically involve antibiotics such as penicillin, amoxicillin, or cephalexin for 7-10 days, with more severe cases requiring intravenous antibiotics 1. The most recent and highest quality study recommends that impetigo, erysipelas, and cellulitis should be managed by antibiotics against Gram-positive bacteria, with empiric therapy for community-acquired MRSA recommended for patients at risk or who do not respond to first-line therapy 1.

From the Research

Difference between Erysipelas and Cellulitis

  • Erysipelas is a form of cellulitis with marked superficial inflammation, typically affecting the lower limbs and the face 2, 3.
  • Cellulitis is a common problem caused by spreading bacterial inflammation of the skin, with redness, pain, and lymphangitis, and can result in local necrosis and abscess formation 2, 3.
  • Erysipelas is usually caused by Group A Beta-hemolytic streptococcus (GABHS, Streptococcus pyogenes), while cellulitis can be caused by streptococci and Staphylococcus aureus 4, 2.
  • Patients with erysipelas typically have a well-demarcated, erythematous, indurated, rapidly spreading patch with a palpable advancing border on the face or extremities, accompanied by fever, chills, and general malaise 4.
  • Cellulitis and erysipelas can have similar symptoms, but erysipelas tends to have more pronounced superficial inflammation and a more defined border 2, 3.

Clinical Characteristics

  • Erysipelas often affects the face or extremities, while cellulitis can affect any part of the body 4, 2.
  • Erysipelas tends to have a more rapid onset and progression than cellulitis 4.
  • Both conditions can lead to complications such as abscess formation, necrotizing fasciitis, septicemia, and lymphedema 4, 2.

Treatment and Prevention

  • Antibiotics are usually effective in treating both erysipelas and cellulitis, but the choice of antibiotic may depend on the suspected causative organism 4, 2.
  • Treatment of predisposing factors, such as diabetes mellitus and immunocompromised states, is also important in preventing recurrence of cellulitis and erysipelas 2, 3.
  • The need for empirical coverage of Staphylococcus aureus in cellulitis/erysipelas is still a topic of debate, with some studies suggesting that it may not be necessary for most patients 5.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Cellulitis and erysipelas.

BMJ clinical evidence, 2008

Research

Cellulitis and erysipelas: prevention.

BMJ clinical evidence, 2015

Research

Erysipelas: a common potentially dangerous infection.

Acta dermatovenerologica Alpina, Pannonica, et Adriatica, 2007

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.